Brokerages Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Target Price at $82.27

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has been given an average recommendation of “Moderate Buy” by the thirteen research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eleven have issued a buy recommendation on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $82.75.

A number of equities research analysts have recently issued reports on the stock. TD Cowen cut their target price on shares of Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday. Morgan Stanley lowered their price objective on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, July 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, October 8th. Wells Fargo & Company started coverage on Ultragenyx Pharmaceutical in a research report on Monday, October 20th. They issued an “overweight” rating and a $65.00 target price for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $105.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, September 5th.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 2,450 shares of the business’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $31.17, for a total transaction of $76,366.50. Following the completion of the sale, the executive vice president owned 73,271 shares in the company, valued at $2,283,857.07. The trade was a 3.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Howard Horn sold 7,942 shares of the firm’s stock in a transaction dated Monday, October 13th. The stock was sold at an average price of $31.51, for a total transaction of $250,252.42. Following the completion of the transaction, the chief financial officer owned 98,227 shares in the company, valued at approximately $3,095,132.77. The trade was a 7.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 10,456 shares of company stock valued at $328,486. 5.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of large investors have recently bought and sold shares of RARE. GAMMA Investing LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 76.2% during the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 323 shares during the last quarter. Parallel Advisors LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 1,061.9% in the 2nd quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 669 shares during the last quarter. Assetmark Inc. boosted its position in Ultragenyx Pharmaceutical by 1,706.7% during the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 1,024 shares during the period. Smartleaf Asset Management LLC grew its stake in Ultragenyx Pharmaceutical by 205.4% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 1,169 shares during the last quarter. Finally, Covestor Ltd grew its stake in Ultragenyx Pharmaceutical by 26.0% during the 3rd quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 369 shares during the last quarter. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Stock Down 1.0%

Shares of RARE opened at $30.63 on Wednesday. The business’s 50 day moving average is $31.47 and its two-hundred day moving average is $32.85. Ultragenyx Pharmaceutical has a 52-week low of $25.81 and a 52-week high of $53.04. The firm has a market cap of $2.95 billion, a price-to-earnings ratio of -5.54 and a beta of 0.30.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.58). The company had revenue of $159.93 million during the quarter, compared to the consensus estimate of $167.42 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The firm’s quarterly revenue was up 14.6% on a year-over-year basis. During the same quarter last year, the firm posted ($1.40) EPS. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. On average, equities analysts expect that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.